From the New England Journal of Medicine
André Lamy, M.D., P.J. Devereaux, M.D., Ph.D., Prabhakaran Dorairaj, M.D., David P. Taggart, Ph.D., Shengshou Hu, M.D., Ernesto Paolasso, M.D., Zbynek Straka, M.D., Leopoldo S. Piegas, M.D., Ahmet Ruchan Akar, M.D., Anil R. Jain, M.D., Nicolas Noiseux, M.D., Chandrasekar Padmanabhan, M.D., Juan-Carlos Bahamondes, M.D., Richard J. Novick, M.D., Prashant Vaijyanath, M.D., Sukesh Kumar Reddy, M.D., Liang Tao, M.D., Pablo A. Olavegogeascoechea, M.D., Balram Airan, M.D., Toomas-Andres Sulling, M.D., Richard P. Whitlock, M.D., Yongning Ou, M.Sc., Janice Pogue, Ph.D., Susan Chrolavicius, B.A., and Salim Yusuf, D.Phil. for the CORONARY Investigators
March 11, 2013
Coronary-artery bypass grafting (CABG) reduces mortality among patients with extensive coronary artery disease.1 CABG is usually performed with the use of cardiopulmonary bypass (on-pump CABG). With this approach, perioperative mortality is about 2%, and myocardial infarction, stroke, or renal failure requiring dialysis develop in an additional 5 to 7% of patients. The technique of performing CABG on a beating heart (off-pump CABG) was developed to reduce perioperative complications, some of which may be related to the use of cardiopulmonary bypass and to the cross-clamping of the aorta associated with the on-pump CABG procedure, and to improve long-term outcomes.
Read the entire article here
An example of a heart attack, which can occur after the use of a performance-enhancing drug. (Photo credit: Wikipedia)